Text Size
129 studies found for:    "HIV Preventive Vaccine" [CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Completed A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN
22 Completed Development of a New HIV Vaccine
Condition: HIV Infections
Intervention: Biological: PolyEnv1
23 Completed Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
24 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
25 Completed Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: EP HIV-1043;   Biological: EP HIV-1090
26 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
27 Suspended Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
Condition: HIV Infections
Interventions: Biological: MRKAd5 HIV-1 gag/pol/nef;   Other: Placebo
28 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Interventions: Biological: gp160 Vaccine (Immuno-AG);   Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: HIVAC-1e
29 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
30 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
31 Unknown † Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
32 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
33 Completed A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
34 Completed A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2
35 Completed Candidate HIV Vaccine
Condition: HIV Infections
Intervention: Drug: VRC-HIVDNA016-00-VP
36 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
37 Completed A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
38 Completed Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
39 Completed Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
Condition: HIV Infections
Intervention: Biological: MVA-mBN32
40 Completed A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years